Group B streptococcus in the Northern Territory in 2023: clindamycin down but not out

Authors

  • Kate E Proudmore Advanced Trainee Infectious Diseases and Acute and General Care Medicine; Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.;Department of Microbiology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
  • Ma Nu Nu Swe Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.; Department of Microbiology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
  • May Leitch Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.; Department of Microbiology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
  • Kim Clayfield Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.; Department of Microbiology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
  • Jann Hennessy Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.; Department of Microbiology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.
  • Rob W Baird Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.; Clinical Microbiologist and Director of Pathology, Territory Pathology, Royal Darwin Hospital, Rocklands Drive TIWI NT 0810 Australia.

DOI:

https://doi.org/10.33321/cdi.2023.47.52

Abstract

-

Downloads

Download data is not yet available.

References

Spellerberg P, Brandt C. Streptococcus. In Versalovich J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, eds. Manual of Clinical Microbiology (10th Edition). Washington DC: American Society for Microbiology Press, 2011; 331–49. doi: https://doi.org/10.1128/9781555816728.ch20.

Yanni M, Stark M, Francis L, Francis JR, McMillan M, Baird R et al. Neonatal group B streptococcal infection in Australia: a case-control study. Pediatr Infect Dis J. 2023;42(5):429–35. doi: https://doi.org/10.1097/INF.0000000000003881.

Therapeutic Guidelines. Prevention of neonatal Streptococcus agalactiae (group B streptococcus) disease. [Internet.] Melbourne: Therapeutic Guidelines Limited; April 2019. [Accessed on 5 May 2023.] Available from: www.tg.org.au.

Garland SM, Cottrill E, Markowski L, Pearce C, Clifford V, Ndisang D et al. Antimicrobial resistance in group B streptococcus: the Australian experience. J Med Microbiol. 2011;60(Pt 2):230–5. doi: https://doi.org/10.1099/jmm.0.022616-0.

Hayes K, Cotter L, Barry L, O’Halloran F. Emergence of the L phenotype in Group B Streptococci in the South of Ireland. Epidemiol Infect. 2017;145(16):3535–42. doi: https://doi.org/10.1017/S0950268817002461.

Gygax SE, Schuyler JA, Kimmel LE, Trama JP, Mordechai E, Adelson ME. Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob Agents Chemother. 2006;50(5):1875–7. doi: https://doi.org/10.1128/AAC.50.5.1875-1877.2006.

Jones S, Newton P, Payne M, Furfaro L. Epidemiology, antimicrobial resistance, and virulence determinants of group B streptococcus in an Australian setting. Front Microbiol. 2022;13:839079. doi: https://doi.org/10.3389/fmicb.2022.839079.

Kadri SS. Key takeaways from the U.S. CDC’s 2019 Antibiotic Resistance Threats Report for frontline providers. Crit Care Med. 2020;48(7):939–45. doi: https://doi.org/10.1097/CCM.0000000000004371.

Barcaite E, Bartusevicius A, Tameliene R, Kliucinskas M, Maleckiene L, Nadisauskiene R. Prevalence of maternal group B streptococcal colonisation in European countries. Acta Obstet Gynecol Scand. 2008;87(3):260–71. doi: https://doi.org/10.1080/00016340801908759.

Janapatla RP, Ho YR, Yan JJ, Wu HM, Wu JJ. The prevalence of erythromycin resistance in group B streptococcal isolates at a University Hospital in Taiwan. Microb Drug Resist. 2008;14(4):293–7. doi: https://doi.org/10.1089/mdr.2008.0853.

Ding Y, Wang Y, Hsia Y, Russell N, Heath PT. Systematic review and meta-analyses of incidence for group B streptococcus disease in infants and antimicrobial resistance, China. Emerg Infect Dis. 2020;26(11):2651–9. doi: https://doi.org/10.3201/eid2611.181414.

Australian Bureau of Statistics. Snapshot of Northern Territory. Highlevel summary data for Northern Territory in 2021. [Webpage.] Canberra: Australian Bureau of Standards; 28 June 2022. Available from: https://www.abs.gov.au/articles/snapshot-nt-2021.

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI supplement M100. Wayne, PA: CLSI; 2022.

The Antimicrobial Use and Resistance in Australia (AURA) Surveillance System. AURA 2021. Fourth Australian report on antimicrobial use and resistance in human health. Sydney: Australian Commission on Safety and Quality in Health Care; 2021. [Accessed on 17 May 2023.] Available from: https://www.safetyandquality.gov.au/sites/default/files/2021-08/AURA_2021_Fourth_Australian_report_on_antimicrobial_use_and_resistance_in_human_health.pdf.

The Royal Hospital for Women. Local operating procedure – clinical. Group B Streptococcus (GBS) Screening And Prophylaxis. Sydney: South Eastern Sydney Local Health District, the Royal Hospital for Women; June 2022. [Accessed on 17 May 2023.] Available from: https://www.seslhd.health.nsw.gov.au/sites/default/files/documents/GBSprophylaxis%202020.pdf.

Government of Western Australia North Metropolitan Health Service (NMHS). Obstetrics And Gynaecology Clinical Practice Guideline. Group B streptococcal disease. Perth: NMHS; 2021. [Accessed on 17 May 2023.] Available from: https://www.kemh.health.wa.gov.au/~/media/HSPs/NMHS/Hospitals/WNHS/Documents/Clinical-guidelines/Obs-Gyn-Guidelines/Group-B-Streptococcal-Disease.pdf.

Downloads

Published

21/09/23

How to Cite

Proudmore, Kate E, Ma Nu Nu Swe, May Leitch, Kim Clayfield, Jann Hennessy, and Rob W Baird. 2023. “Group B Streptococcus in the Northern Territory in 2023: Clindamycin down But Not Out”. Communicable Diseases Intelligence 47 (September). https://doi.org/10.33321/cdi.2023.47.52.

Issue

Vol. 47 (2023)

Section

Short report

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.